NetScientific

Founded in 2010, Vortex Biosciences specializes in liquid biopsy technology for cancer diagnosis and monitoring. The company's flagship product, the VTX-1 Liquid Biopsy System, automates the isolation of viable circulating tumor cells directly from whole blood.

Founded in 2011, Sofant Technologies specializes in designing and licensing smart antenna and tunable RF solutions for smartphone and tablet manufacturers. Its offerings include compact smart antenna solutions, tunable impedance matching modules, RF MEMS capacitors, and phase shifters, aiming to enhance performance while reducing power consumption and heat.

Founded in 2010, Vortex Biosciences specializes in liquid biopsy technology for cancer diagnosis and monitoring. The company's flagship product, the VTX-1 Liquid Biopsy System, automates the isolation of viable circulating tumor cells directly from whole blood.

Q-Bot is a London-based robotics company that develops robotic tools capable of moving under floors to access and insulate floorboards. It also offers a robotics platform that can survey, evaluate and apply treatments in underfloor spaces, enabling insulation work with minimal disruption. By applying insulation through automated systems, Q-Bot aims to reduce heat loss and draughts, improving home energy efficiency and indoor comfort. Founded in 2012, the company operates in the United Kingdom and focuses on underfloor retrofit technology that combines hardware and software to streamline insulation installation.

Founded in 2010, Vortex Biosciences specializes in liquid biopsy technology for cancer diagnosis and monitoring. The company's flagship product, the VTX-1 Liquid Biopsy System, automates the isolation of viable circulating tumor cells directly from whole blood.

Q-Bot is a London-based robotics company that develops robotic tools capable of moving under floors to access and insulate floorboards. It also offers a robotics platform that can survey, evaluate and apply treatments in underfloor spaces, enabling insulation work with minimal disruption. By applying insulation through automated systems, Q-Bot aims to reduce heat loss and draughts, improving home energy efficiency and indoor comfort. Founded in 2012, the company operates in the United Kingdom and focuses on underfloor retrofit technology that combines hardware and software to streamline insulation installation.

EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

Founded in 2011, Sofant Technologies specializes in designing and licensing smart antenna and tunable RF solutions for smartphone and tablet manufacturers. Its offerings include compact smart antenna solutions, tunable impedance matching modules, RF MEMS capacitors, and phase shifters, aiming to enhance performance while reducing power consumption and heat.

PointGrab is a technology company that develops machine learning powered sensing software for optical IoT devices used in commercial real estate and building automation. Its solutions include an optical sensing module that converts visual signals into analytics for occupancy sensing, ambient light sensing, and occupants’ behavior analytics, enabling real estate owners and facility managers to optimize space utilization, improve efficiency, and reduce costs while prioritizing employee privacy and welfare. The company also provides a sensing data system that collects workspace behavior data such as occupancy, object detection, virtual line traffic, and people counting to support sustainability compliance and enhance the employee experience. PointGrab was founded in 2008 and is based in Hod Hasharon, Israel, and is recognized as a leader in occupancy sensing and smart building features for commercial real estate.

Founded in 2015, SageTech Medical develops innovative anesthetic technology for human and veterinary healthcare providers. Its patented process captures, extracts, and purifies inhalational anaesthetic agents, reducing costs and environmental pollution. The company offers solutions ranging from industrial-scale bulk capture to integrated recycling systems within anaesthetic machines.

ProAxsis Ltd. is a biotechnology company that focuses on developing laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers associated with various diseases. The company's innovative tests utilize patented ProteaseTags®, which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. ProAxsis has validated several active protease species as biomarkers of disease activity in conditions such as cancer, infections, and respiratory diseases, including bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). In 2016, the company registered its first immunoassay for the specific measurement of active neutrophil elastase, a significant biomarker for lung infection and inflammation, with a European CE Mark, highlighting its commitment to advancing medical diagnostics.

EMV Capital is a venture capital firm specializing in early-stage investments in high-growth deep tech companies focused on life science, sustainability, and industrial sectors across the UK and internationally.

ProAxsis Ltd. is a biotechnology company that focuses on developing laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers associated with various diseases. The company's innovative tests utilize patented ProteaseTags®, which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. ProAxsis has validated several active protease species as biomarkers of disease activity in conditions such as cancer, infections, and respiratory diseases, including bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). In 2016, the company registered its first immunoassay for the specific measurement of active neutrophil elastase, a significant biomarker for lung infection and inflammation, with a European CE Mark, highlighting its commitment to advancing medical diagnostics.

Nuada is a vertically integrated company specializing in carbon capture technology aimed at decarbonizing heavy industries. The firm develops next-generation point-source capture solutions designed to facilitate energy-efficient CO2 filtration for industrial emitters in sectors that are difficult to decarbonize. By offering innovative technologies, Nuada enables these industries to meet their Net Zero targets while minimizing financial impacts. The company is committed to providing effective environmental solutions that address the challenges of carbon emissions in various industrial applications.